HDGFL2 and Miyoshi myopathy: An independent cohort of patients with relapsed MM after single bortezomib treatment (APEX, SUMMIT, and CREST trials; n = 188) from Mulligan’s study (26) indicated that low expression of HRP2 predicted a worse trend of overall survival (OS) (Figure 1I) that was also seen in Zhan’s cohort of pretreatment bone marrow aspirates from patients with MM (Supplemental Figure 1E and ref. 27).